12:00 AM
Jun 18, 2012
 |  BC Week In Review  |  Company News  |  Other News

Amgen hematology news

The U.S. Supreme Court agreed to hear a challenge from Amgen on a securities fraud suit alleging the biotech misled investors about the safety of anemia drugs Aranesp darbepoetin alfa and Epogen epoetin alfa. At issue is whether plaintiffs...

Read the full 204 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >